|

Pralsetinib Clinical Trials

5 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Also known as: GAVRETO, Gavreto, Gavreto (US), Gavreto®

Pipeline

Phase 2: 3Phase 4: 1

Top Sponsors

  • West China Hospital1
  • Sun Yat-sen University1
  • Seoul National University Bundang Hospital1
  • Rigel Pharmaceuticals1
  • Genentech, Inc.1

Indications

  • Cancer5
  • Lung Cancer3
  • Locally Advanced Thyroid Gland Carcinoma1
  • Mutation1
  • Advanced Malignancies1

Other4 trials

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Phase 2
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Phase 2
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
Phase 4

Duarte, California1 trial

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

City of Hope Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.